DGL Licorice for GERD and Stomach Health

Regular licorice root has a legitimate history as a gastric remedy — ancient Egyptian, Greek, and Chinese medical traditions all used it for stomach ailments. The problem is glycyrrhizin, the compound that gives licorice its characteristic sweetness and also causes sodium retention, potassium loss, elevated blood pressure, and in high doses, potentially serious cardiac arrhythmias.

Deglycyrrhizinated licorice (DGL) removes glycyrrhizin while retaining the polyphenols and flavonoids responsible for the stomach-soothing and mucosal-protective effects. The result is a supplement that can be used at therapeutic doses without the cardiovascular risks that make regular licorice root unsuitable for ongoing use.

What DGL Contains and How It Works

After glycyrrhizin removal, DGL retains a complex of biologically active compounds, including glabridin, liquiritin, isoliquiritigenin, and various flavonoids. These compounds work through several complementary mechanisms to protect and repair the stomach and esophageal lining:

Stimulation of mucus secretion: DGL compounds stimulate the production of mucin — the gel-forming proteins that constitute the protective mucus layer coating the stomach wall. Mucus is the stomach's primary defense against its own acid. Conditions like gastric ulcers and gastritis often involve impaired mucus production or disruption of the mucus layer. DGL reinforces this defense.

Promotion of prostaglandin synthesis: Prostaglandins (particularly PGE2) are signaling molecules that regulate gastric mucosal protection. They increase blood flow to the gastric mucosa, stimulate bicarbonate secretion, and enhance the mucus barrier. DGL flavonoids have been shown in animal and cell culture studies to upregulate prostaglandin synthesis in gastric tissue — the same mechanism exploited by misoprostol, a pharmaceutical used to protect the stomach in patients on NSAIDs.

Inhibition of H. pylori: Several DGL compounds, particularly glabridin and licochalcone A, have demonstrated inhibitory activity against Helicobacter pylori in laboratory studies. Whether this translates to clinically meaningful H. pylori suppression in humans at supplement doses is not established, but the in vitro activity is notable.

Anti-inflammatory activity: Licorice flavonoids inhibit NF-κB signaling and reduce production of inflammatory cytokines in gastric tissue. Glabridin in particular has demonstrated COX-2 inhibitory activity — a mechanism relevant to reducing gastric inflammation without the mucosal damage caused by conventional NSAIDs that inhibit both COX-1 and COX-2.

Evidence for Gastric Ulcers

The most substantive clinical evidence for DGL comes from gastric and peptic ulcer trials conducted primarily in the 1970s and 1980s. A double-blind trial published in the British Medical Journal (1972) compared DGL (760mg three times daily) to a pharmaceutical antacid preparation (cimetidine) in patients with gastric ulcers confirmed by endoscopy. After four weeks of treatment, endoscopic healing rates were not significantly different between the two groups, suggesting DGL produced comparable results to antacid therapy.

A subsequent trial by the same research group compared DGL to cimetidine specifically in duodenal ulcer patients and found DGL produced ulcer healing rates similar to the pharmaceutical, with lower recurrence rates at six-month follow-up in the DGL group.

These studies are dated by modern clinical trial standards — sample sizes were modest, methodologies have evolved, and pharmacological acid suppression (PPIs) is more effective than H2 blockers for acute healing. Nevertheless, the evidence represents genuinely controlled trial data, not just traditional use or mechanistic rationale.

DGL for GERD

GERD (gastroesophageal reflux disease) involves repeated acid exposure to the esophageal mucosa, causing irritation, inflammation, and potentially Barrett's esophagus over time.

DGL's role in GERD is protective and symptomatic rather than acid-suppressing. It does not reduce acid production — this is a critical distinction from PPIs and H2 blockers. What it does do is:

Reinforce the esophageal mucus layer, providing a buffer against acid exposure
Reduce inflammation in the esophageal lining
Potentially accelerate healing of irritated esophageal tissue

This makes DGL most useful as an adjunct to conventional GERD management, not a replacement for acid-suppressive therapy in patients with significant esophageal damage. For mild to moderate GERD, particularly in people trying to reduce PPI reliance or manage breakthrough symptoms, DGL is a reasonable option with a favorable safety profile.

A practical consideration: DGL is most effective for GERD when taken 15-20 minutes before meals and at bedtime, when acid secretion and reflux risk are highest. Chewable formulations are preferred (more below on why).

Why Chewable DGL Is Preferred

Most DGL clinical trials used chewable tablets rather than capsules. The rationale is physiological: chewing disperses the DGL compounds throughout the mouth, esophagus, and upper stomach as you swallow, maximizing contact time with the mucosa where it's needed.

Swallowing a DGL capsule means the compound passes quickly through the stomach with less opportunity to adhere to and coat the upper GI mucosa. Chewing mechanically breaks down the tablet and mixes it with saliva, initiating the coating process in the mouth and throughout the esophagus during swallowing.

For esophageal symptoms and GERD specifically, chewable DGL has a clear advantage. For purely lower GI or stomach conditions, the distinction may matter less.

Dosing Protocol

The standard dose used in clinical trials is 380-760mg of DGL extract per dose, two to four times daily. Most commercial products provide 380mg per chewable tablet.

For active GERD symptoms: 380-760mg (one to two tablets) chewed 15-20 minutes before meals and at bedtime. The pre-meal timing ensures the protective layer is in place before acid secretion peaks during eating.

For gastric ulcer support: 760mg three times daily, taken 20 minutes before meals, for 8-12 weeks. This mirrors the dosing used in older clinical trials.

For ongoing gastric maintenance: 380mg once or twice daily as needed.

For immediate symptom relief: Some people chew one DGL tablet at symptom onset for acute relief. This is less well-studied but mechanistically sensible — the coating effect is fairly rapid.

DGL vs. Regular Licorice Root

This distinction matters enough to address directly. Regular licorice root supplements, licorice candy (especially the real kind), and herbal teas containing significant licorice can deliver meaningful amounts of glycyrrhizin. Chronic intake of more than 100mg of glycyrrhizin daily — achievable with moderate licorice supplementation — can cause:

Elevated blood pressure (pseudohyperaldosteronism)
Sodium retention and edema
Hypokalemia (low potassium), which can cause muscle weakness and cardiac arrhythmias
Interference with certain medications, including corticosteroids and antihypertensives

These risks are dose-dependent and more pronounced in people with existing hypertension, cardiovascular disease, or kidney disease.

DGL at standard doses is safe because glycyrrhizin is removed. Studies specifically evaluating the cardiovascular safety of DGL have confirmed no significant effect on blood pressure or aldosterone at therapeutic doses.

Combining DGL with Other Gut Health Supplements

DGL can be reasonably combined with:

Slippery elm: Both provide mucilaginous/coating effects. Using both may enhance mucosal coverage, particularly if symptoms involve both upper and lower GI tract.
Zinc carnosine: Complementary mechanisms — DGL stimulates mucus and prostaglandins, zinc carnosine adheres to the gastric mucosa and promotes tissue healing. Combination use is common in integrative gastroenterology protocols.
Aloe vera: Another mucosa-soothing agent with anti-inflammatory properties. Combination use has some traditional support.

Avoid combining DGL with medications that are affected by licorice compounds, including some antihypertensives. While DGL removes glycyrrhizin, some residual flavonoids may have modest CYP enzyme interactions at high doses. Disclose DGL use to your prescribing physician if you take cardiovascular medications.

Who DGL Is Appropriate For

People with GERD seeking a natural adjunct to reduce breakthrough symptoms
Those with gastric or duodenal ulcers wanting mucosal support alongside conventional therapy
Patients recovering from gastritis or H. pylori eradication therapy (to support mucosal repair)
People trying to reduce PPI dependence (under medical guidance)
Anyone with chronic NSAID use wanting gastric protection
People with functional dyspepsia and upper abdominal discomfort

The Bottom Line

DGL licorice removes the problematic glycyrrhizin compound while retaining genuine stomach-protective properties: stimulation of mucus production, prostaglandin synthesis, and anti-inflammatory activity in the gastric mucosa. Clinical trial evidence from gastric ulcer studies is modest but real. The mechanism for GERD support is plausible and consistent with traditional use. Standard dose is 380-760mg chewable tablets taken 15-20 minutes before meals. It does not replace acid-suppressive therapy for significant GERD but is a well-tolerated adjunct with a strong safety profile — making it one of the more sensible herbal options for upper GI health.

Track your GERD supplements and symptoms to see what's actually improving your baseline. Use Optimize free.